Soluble CD4 molecules modified to prolong circulating half-life

Details Soluble CD4 molecules modified to prolong circulating half-life Soluble CD4 molecules modified to prolong circulating half-life

1991-02-22

1993-08-10

Wax, Robert A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530350, 530395, 530402, A61K 3702, C07K 1514

Patent

active

052349055

ABSTRACT:
A method for extending soluble CD4 serum half-life in mammals is described. The method comprises modifying soluble CD4 glycosylation so as to inhibit clearance from serum. In a preferred embodiment, clearance by hepatocyte galactose receptors is inhibited by removal of soluble CD4 terminal sialic residues followed by oxidation of exposed galactose residues. The modified soluble CD4 molecules are demonstrated to possess extended serum half-life.

REFERENCES:
patent: 4184917 (1980-01-01), Dorner et al.
patent: 4911911 (1986-12-01), Casellas et al.
patent: 5109123 (1992-04-01), Reinherz et al.
patent: 5116944 (1992-05-01), Sivam et al.
Watanabe, M., (1992), "Chimpanzees Immunized with Recombinant Soluble CD4 Develop Anti-Self CD4 Antibody Responses with Anti-Human Immunodeficiency Virus Activity", Proc. Natl. Acad. Sci. USA, 89:5103-5107.
Gross et al., Eur. J. Biochem., 173:653-659, (1988), "Involvement of Various Organs in the Initial Plasma Clearance of Differently Glycosylated Rat Liver Secretory Proteins".
Peterson et al., (1988), Cell, 54:65-72.
Schooley et al., (1990), Ann. Int. Med., 112:247-253.
Larsen et al., (1989), Blood, 73:1842-1850.
Roth et al., (1965), Anal. Biochem., 10:35-52.
Schiff et al., (1986), Hepatology, 6:837-847.
Morell et al., (1971), J. Biol. Chem., 246:1461-1467.
Morell et al., (1968), J. Biol. Chem., 243:155-159.
Ashwell et al., (1982), Ann. Rev. Biochem., 51:531-554.
Fukuda et al., (1989), Blood, 73:84-89.
Hussey et al., (1988), Nature, 331:78-81.
Chao et al., (1989), J. Biol. Chem., 264:5812-5817.
Maddon et al., (1985), Cell, 42:93-104.
Morell et al., (1966), J. Biol. Chem., 241:3745-3749.
van den Hamer et al., (1970), J. Biol. Chem., 245:4397-4402.
Pyatak, (1980), Res. Comm. Chem. Path. Pharm., 29:113-127.
Fahey et al., "Status of Immune-based Therapies in HIV . . . ", Clin. Exp. Immunol., 88:1-5, Apr. 1992.
S. Yu et al., Archives of Biochemistry and Biophysics, 179:477-485, 1977.
K.-J. Kao et al., Journal of Biological Chemistry, 255:10134-10139, 1980.
J. M. Sodetz et al., Journal of Biological Chemistry, 252:5538-5546, 1977.
Carr et al., J. Biol. Chem., 264:21286-21295, Dec. 15, 1989.

Affiliated with

Also associated with

Rating

Soluble CD4 molecules modified to prolong circulating half-life does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soluble CD4 molecules modified to prolong circulating half-life, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble CD4 molecules modified to prolong circulating half-life will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1725201